Table 3.

Multivariate analysis of the survival outcomes by androgen receptor status

ModelsnHR (95% CI)
CasesEndpointsAR-negativeAR-positive
Breast cancer specific survival
All cases
Model 114672751.000.78 (0.60–1.03)
Model 214672751.000.96 (0.69–1.34)
ER-positive cases
Model 111642051.000.59 (0.41–0.85)
Model 311642051.000.68 (0.47–0.99)
ER-negative cases
Model 1303701.001.46 (0.91–2.33)
Model 3303701.001.59 (0.94–2.68)
Recurrence-free interval
All cases
Model 114672881.000.80 (0.62–1.05)
Model 214672881.000.99 (0.72–1.36)
ER-positive cases
Model 111642171.000.62 (0.44–0.89)
Model 311642171.000.72 (0.50–1.05)
ER-negative cases
Model 1303711.001.39 (0.87–2.22)
Model 3303711.001.54 (0.92–2.58)
Overall survival
All cases
Model 114675761.000.90 (0.74–1.10)
Model 214675761.000.89 (0.71–1.13)
ER-positive cases
Model 111644601.000.68 (0.52–0.88)
Model 311644601.000.70 (0.53–0.91)
ER-negative cases
Model 13031161.001.48 (1.02–2.13)
Model 33031161.001.42 (0.95–2.13)

NOTE: Model 1: Adjust for age at diagnosis (years). Model 2: Adjust for age at diagnosis (years), ER status (positive, negative), date of diagnosis (months), disease stage (I, II, III), grade (I, II, III), radiation treatment (yes, no, missing), chemotherapy and hormonal treatment (no/no, yes/no, no/yes, yes/yes, missing). Model 3: Adjust for age at diagnosis (years), date of diagnosis (months), disease stage (I, II, III), grade (I, II, III), radiation treatment (yes, no, missing), chemotherapy and hormonal treatment (no/no, yes/no, no/yes, yes/yes, missing).